https://www.thebostonexaminer.com/article/910349585-sitestream-a-polaris-group-company-now-an-awarded-vendor-by-the-north-carolina-sheriffs-association The Boston Examiner en PressRelease 2026-05-04T22:55:52+00:00 Sitestream, A Polaris Group Company, now an 'Awarded Vendor' by the North Carolina Sheriffs' Association https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24847402-north-carolina-sheriffs-procur-500x500.jpeg https://www.thebostonexaminer.com/article/910268013-medical-cannabis-rescheduling-increases-need-for-clinician-education-theanswerpage-com-launches-cannabis-cme-ce-course The Boston Examiner en PressRelease 2026-05-04T17:27:40+00:00 Medical Cannabis Rescheduling Increases Need for Clinician Education: TheAnswerPage.com Launches Cannabis CME/CE Course https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24847051-www-theanswerpage-com-cannabis-1536x1024.png https://www.thebostonexaminer.com/article/910262736-actually-health-announces-virtual-care-membership-that-gets-smarter-with-every-patient The Boston Examiner en PressRelease 2026-05-04T17:23:26+00:00 Actually Health Announces Virtual Care Membership That Gets Smarter With Every Patient https://www.thebostonexaminer.com/article/910286370-massachusetts-report-why-a-dedicated-local-mortgage-lender-wins-in-the-current-housing-market The Boston Examiner en PressRelease 2026-05-04T16:59:58+00:00 Massachusetts Report: Why a Dedicated Local Mortgage Lender Wins in the Current Housing Market https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24847087-main-street-home-loans-500x500.png https://www.thebostonexaminer.com/article/910282603-influential-women-highlights-weronika-bianka-nowak-leading-u-s-renewable-energy-expansion-at-greenvolt The Boston Examiner en PressRelease 2026-05-04T16:38:56+00:00 Influential Women Highlights Weronika Bianka Nowak: Leading U.S. Renewable Energy Expansion at Greenvolt https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24847068-weronika-bianka-nowak1-354x358.png https://www.thebostonexaminer.com/article/910251762-lionbridge-names-sebastian-bretschneider-chief-executive-officer The Boston Examiner en PressRelease 2026-05-04T16:00:00+00:00 Lionbridge Names Sebastian Bretschneider Chief Executive Officer https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24846853-sebastian-bretschneider-461x461.jpeg https://www.thebostonexaminer.com/article/910260314-creatio-sets-a-new-standard-for-enterprise-software-pricing-in-the-age-of-ai The Boston Examiner en PressRelease 2026-05-04T14:00:31+00:00 Creatio Sets a New Standard for Enterprise Software Pricing in the Age of AI https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24846909-unlimited-pricing-1280x628.png https://www.thebostonexaminer.com/article/909118729-lydonia-showcases-proven-invoice-processing-solution-delivering-measurable-finance-results The Boston Examiner en PressRelease 2026-05-04T12:00:00+00:00 Lydonia Showcases Proven Invoice Processing Solution Delivering Measurable Finance Results https://www.thebostonexaminer.com/article/909690194-c10-labs-and-pegasystems-launch-applied-ai-accelerator-in-cambridge-for-summer-2026 The Boston Examiner en PressRelease 2026-05-04T12:00:00+00:00 C10 Labs and Pegasystems launch Applied AI Accelerator in Cambridge for Summer 2026 https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24845724-c10-labs-logo-1680x145.png https://www.thebostonexaminer.com/article/909951098-buyers-brokers-only-celebrates-30-years-of-the-national-association-of-exclusive-buyer-agents The Boston Examiner en PressRelease 2026-05-04T10:45:00+00:00 Buyers Brokers Only Celebrates 30 Years of the National Association of Exclusive Buyer Agents https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24757193-david-kres-ii-828x1076.png https://www.thebostonexaminer.com/article/910351888-erasca-inc-investors-should-contact-block-leviton-llp-to-learn-more-about-securities-fraud-investigation The Boston Examiner en PressRelease 2026-05-04T22:02:11+00:00 Erasca, Inc. Investors Should Contact Block & Leviton LLP to Learn More About Securities Fraud Investigation https://ml.globenewswire.com/media/582f8ff5-dda1-458c-b0b6-cc833c566289/small/block-leviton-llp-logo.jpg https://www.thebostonexaminer.com/article/910342555-cogent-communications-holdings-inc-investigated-for-securities-fraud-by-block-leviton-investors-should-contact-the-firm-to-potentially-recover The Boston Examiner en PressRelease 2026-05-04T21:29:23+00:00 Cogent Communications Holdings, Inc. Investigated for Securities Fraud by Block & Leviton: Investors Should Contact the Firm to Potentially Recover Losses https://ml.globenewswire.com/media/582f8ff5-dda1-458c-b0b6-cc833c566289/small/block-leviton-llp-logo.jpg https://www.thebostonexaminer.com/article/910333422-tango-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4 The Boston Examiner en PressRelease 2026-05-04T20:31:00+00:00 Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/d6e37a27-2e33-43bb-ae05-bfb0dedbf190/small/tango-logo-png.png https://www.thebostonexaminer.com/article/910333368-vor-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4 The Boston Examiner en PressRelease 2026-05-04T20:30:00+00:00 Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/dde67700-b1b4-40c4-b930-13bd71804762/small/vor-wordmark-rgb-fullcolor-070920-png.png https://www.thebostonexaminer.com/article/910333494-cabot-corporation-board-increases-dividend The Boston Examiner en PressRelease 2026-05-04T20:30:00+00:00 Cabot Corporation Board Increases Dividend https://ml.globenewswire.com/media/11e9c65d-6db0-4438-9e9e-67e36babd32e/small/cabot-logo-full-color-rmark-2-png.png https://www.thebostonexaminer.com/article/910333482-great-elm-capital-corp-announces-first-quarter-2026-financial-results The Boston Examiner en PressRelease 2026-05-04T20:15:00+00:00 Great Elm Capital Corp. Announces First Quarter 2026 Financial Results https://ml.globenewswire.com/media/c67af62e-a4ad-40ad-84f3-30e505895084/small/gecc-new-logo-jpg.jpg https://www.thebostonexaminer.com/article/910324625-everquote-announces-first-quarter-2026-financial-results The Boston Examiner en PressRelease 2026-05-04T20:05:00+00:00 EverQuote Announces First Quarter 2026 Financial Results https://ml.globenewswire.com/media/86005bfc-f760-4c2f-9bfc-d896152a9bea/small/everquote-jpg.jpg https://www.thebostonexaminer.com/article/910324720-aktis-oncology-initiates-phase-1b-clinical-trial-for-aky-2519-a-b7-h3-miniprotein-radioconjugate-in-metastatic-castration-resistant-prostate-cancer The Boston Examiner en PressRelease 2026-05-04T20:05:00+00:00 Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC) https://ml.globenewswire.com/media/490bbb9a-2b27-4a72-8d7a-333387326d8b/small/aktis-rgb-png.png https://www.thebostonexaminer.com/article/910324723-akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 The Boston Examiner en PressRelease 2026-05-04T20:05:00+00:00 Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/c7f3708e-3328-4668-95c6-e7646efd653a/small/akebia-logo-fullcolor-rgb-png.png https://www.thebostonexaminer.com/article/910324680-cps-technologies-corp-announces-hiring-of-new-chief-financial-officer The Boston Examiner en PressRelease 2026-05-04T20:02:00+00:00 CPS Technologies Corp. Announces Hiring of New Chief Financial Officer https://ml.globenewswire.com/media/91f4960f-2c05-4602-bc3d-03e1914bb19c/small/cps-logo-090121-png.png https://www.thebostonexaminer.com/article/910324495-praxis-precision-medicines-to-report-first-quarter-2026-financial-results-on-thursday-may-7-2026-and-participate-in-upcoming-investor-conference The Boston Examiner en PressRelease 2026-05-04T20:01:00+00:00 Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference https://ml.globenewswire.com/media/bff1e728-30ed-46c6-81e1-8bbc795929c0/small/01-primarylogo-color-bluex-100-jpg.jpg https://www.thebostonexaminer.com/article/910324629-hemab-therapeutics-announces-closing-of-upsized-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares The Boston Examiner en PressRelease 2026-05-04T20:01:00+00:00 Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares https://ml.globenewswire.com/media/M2UyM2ExNWYtYTJjYi00M2RhLTkwZGEtNjZlYTUyMzI4NTI4LTEzMjE4MjEtMjAyNi0wNS0wNC1lbg==/tiny/Hemab-Therapeutics-Inc-.png https://www.thebostonexaminer.com/article/910324725-cps-technologies-announces-first-quarter-2026-financial-results The Boston Examiner en PressRelease 2026-05-04T20:01:00+00:00 CPS Technologies Announces First Quarter 2026 Financial Results https://ml.globenewswire.com/media/91f4960f-2c05-4602-bc3d-03e1914bb19c/small/cps-logo-090121-png.png https://www.thebostonexaminer.com/article/910324702-norwegian-cruise-line-holdings-ltd-investigated-for-securities-fraud-violations-by-block-leviton-nclh-investors-should-contact-the-firm-to The Boston Examiner en PressRelease 2026-05-04T19:43:25+00:00 Norwegian Cruise Line Holdings Ltd. Investigated for Securities Fraud Violations by Block & Leviton: NCLH Investors Should Contact the Firm to Possibly Recover Losses https://ml.globenewswire.com/media/582f8ff5-dda1-458c-b0b6-cc833c566289/small/block-leviton-llp-logo.jpg https://www.thebostonexaminer.com/article/910272541-sophos-celebrates-22-leaders-named-to-2026-crn-women-of-the-channel-list The Boston Examiner en PressRelease 2026-05-04T14:56:39+00:00 Sophos Celebrates 22 Leaders Named to 2026 CRN Women of the Channel List https://ml.globenewswire.com/media/35db908a-b7b8-4ce0-b920-69875da346ba/small/sophos-1200x628-png.png https://www.thebostonexaminer.com/article/910266576-polar-id-kills-the-cutout-metalenz-launches-simple-secure-face-authentication-working-under-the-phone-display The Boston Examiner en PressRelease 2026-05-04T14:45:00+00:00 Polar ID kills the cutout — Metalenz launches simple, secure, face authentication working under the phone display https://ml.globenewswire.com/media/87ed8f82-bc27-4f4a-bd6f-03b30d8f16ab/small/metalenzlogoprtemplate-png.png https://www.thebostonexaminer.com/article/910262638-stop-shop-expands-grocery-delivery-for-customers-with-uber-eats The Boston Examiner en PressRelease 2026-05-04T14:00:00+00:00 Stop & Shop Expands Grocery Delivery for Customers with Uber Eats https://ml.globenewswire.com/media/507f1e94-782c-4a66-beab-7ffebd4375cf/small/stop-shop-logo-jpg.jpg https://www.thebostonexaminer.com/article/910258286-alpha-tau-announces-100-local-disease-control-rate-and-favorable-safety-profile-observed-in-alpha-dart-pancreatic-cancer-trials-presented-at-ddw The Boston Examiner en PressRelease 2026-05-04T13:17:21+00:00 Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026 https://ml.globenewswire.com/media/a9de6f03-a487-4934-98e9-d25cdb4c8bed/small/atm-logo-jpg.jpg https://www.thebostonexaminer.com/article/910253114-aura-biosciences-announces-pricing-of-260-million-public-offering-of-common-stock-and-pre-funded-warrants The Boston Examiner en PressRelease 2026-05-04T13:03:06+00:00 Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants https://ml.globenewswire.com/media/92103c30-8e5a-4502-9ec4-0f3b3bd9bb83/small/aura-biosciences-1c-orange-large-jpg.jpg https://www.thebostonexaminer.com/article/910247613-bicara-therapeutics-to-report-first-quarter-2026-financial-results-and-business-updates-on-may-11-2026-at-8-30-am-et The Boston Examiner en PressRelease 2026-05-04T12:30:00+00:00 Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET https://ml.globenewswire.com/media/fdf5e06f-0748-428a-8f90-b0a1c6f7bdf3/small/bicara-logo-struck-png.png https://www.thebostonexaminer.com/article/910242598-candel-therapeutics-to-host-investor-conference-call-following-presentation-of-extended-data-from-phase-3-trial-of-aglatimagene-besadenovec-in The Boston Examiner en PressRelease 2026-05-04T12:05:00+00:00 Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting https://ml.globenewswire.com/media/8b82e1e3-4a67-4472-a7c8-05f9d24c9bb0/small/candel-logo-fullcolor-4-png.png https://www.thebostonexaminer.com/article/910242438-rhythm-pharmaceuticals-announces-new-data-presentations-in-acquired-hypothalamic-obesity-at-pediatric-endocrine-society The Boston Examiner en PressRelease 2026-05-04T12:00:00+00:00 Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society https://ml.globenewswire.com/media/b767aaa5-9915-465f-9233-d97757f4e387/small/rhythm-logo-rgb-jpg-registration-mark-jpg.jpg https://www.thebostonexaminer.com/article/910242527-ahold-delhaize-usa-brands-expand-on-demand-grocery-delivery-with-uber-eats The Boston Examiner en PressRelease 2026-05-04T12:00:00+00:00 Ahold Delhaize USA Brands Expand On-Demand Grocery Delivery with Uber Eats https://ml.globenewswire.com/media/4cbc8588-0404-49fd-93f1-e854b79cd78c/medium/ahold-delhaize-usa-brands-expand-on-demand-grocery-delivery.png https://www.thebostonexaminer.com/article/910242538-lifeward-announces-new-rewalk-data-presented-at-asia-2026-conference-demonstrating-a-comprehensive-longitudinal-safety-analysis-for-a-powered The Boston Examiner en PressRelease 2026-05-04T12:00:00+00:00 Lifeward Announces New ReWalk® Data Presented at ASIA 2026 Conference Demonstrating a Comprehensive Longitudinal Safety Analysis for a Powered Exoskeleton https://ml.globenewswire.com/media/9343d7ac-5bc7-4a60-a2c9-a41bf7b5e007/small/lifeward-full-logo-rgb-for-web-01-jpg.jpg https://www.thebostonexaminer.com/article/910242578-akebia-therapeutics-announces-vadadustat-post-hoc-win-statistics-analysis-demonstrating-statistically-significant-reduction-in-mortality-and The Boston Examiner en PressRelease 2026-05-04T12:00:00+00:00 Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology https://ml.globenewswire.com/media/c7f3708e-3328-4668-95c6-e7646efd653a/small/akebia-logo-fullcolor-rgb-png.png https://www.thebostonexaminer.com/article/910237928-emerging-drugs-market-to-reach-558-0-billion-by-2030-driven-by-biologics-innovation-and-regulatory-support The Boston Examiner en PressRelease 2026-05-04T11:34:01+00:00 Emerging Drugs Market to Reach $558.0 Billion by 2030, Driven by Biologics Innovation and Regulatory Support https://ml.globenewswire.com/media/d0c282b6-d496-45a8-a941-33fa5c3e824c/small/bcc-logo-1200-630-png.png https://www.thebostonexaminer.com/article/910233645-seres-therapeutics-presents-preclinical-data-at-digestive-disease-week-ddw-2026-supporting-ser-603-a-next-generation-cultivated-live-biotherapeutic The Boston Examiner en PressRelease 2026-05-04T11:00:00+00:00 Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease https://ml.globenewswire.com/media/f8c3ad50-d1a3-457d-b0c7-8f9237db7f93/small/seres-logo-png.png https://www.thebostonexaminer.com/article/910224348-aura-biosciences-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants The Boston Examiner en PressRelease 2026-05-04T10:03:00+00:00 Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants https://ml.globenewswire.com/media/92103c30-8e5a-4502-9ec4-0f3b3bd9bb83/small/aura-biosciences-1c-orange-large-jpg.jpg https://www.thebostonexaminer.com/article/910224335-aura-biosciences-announces-ceo-transition-as-company-advances-phase-3-compass-trial-toward-enrollment-completion The Boston Examiner en PressRelease 2026-05-04T10:01:00+00:00 Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion https://ml.globenewswire.com/media/92103c30-8e5a-4502-9ec4-0f3b3bd9bb83/small/aura-biosciences-1c-orange-large-jpg.jpg https://www.thebostonexaminer.com/article/910184202-molecular-partners-to-hold-oral-presentations-on-dll3-targeting-radio-darpin-candidate-mp0712-at-multiple-upcoming-scientific-conferences The Boston Examiner en PressRelease 2026-05-04T05:00:00+00:00 Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences https://ml.globenewswire.com/media/ac0d728a-e43a-4d2b-a9c5-52e74d0dd1eb/small/molecularpartners-logo-jpg.jpg